BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15177446)

  • 21. Selective nitrile inhibitors to modulate the proteolytic synergism of cathepsins S and F.
    Frizler M; Schmitz J; Schulz-Fincke AC; Gütschow M
    J Med Chem; 2012 Jun; 55(12):5982-6. PubMed ID: 22686657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K.
    Barrett DG; Boncek VM; Catalano JG; Deaton DN; Hassell AM; Jurgensen CH; Long ST; McFadyen RB; Miller AB; Miller LR; Payne JA; Ray JA; Samano V; Shewchuk LM; Tavares FX; Wells-Knecht KJ; Willard DH; Wright LL; Zhou HQ
    Bioorg Med Chem Lett; 2005 Aug; 15(15):3540-6. PubMed ID: 15982880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 3,4-disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P3 elements for potency and selectivity.
    Setti EL; Davis D; Janc JW; Jeffery DA; Cheung H; Yu W
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1529-34. PubMed ID: 15713422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specificity determinants of human cathepsin s revealed by crystal structures of complexes.
    Pauly TA; Sulea T; Ammirati M; Sivaraman J; Danley DE; Griffor MC; Kamath AV; Wang IK; Laird ER; Seddon AP; Ménard R; Cygler M; Rath VL
    Biochemistry; 2003 Mar; 42(11):3203-13. PubMed ID: 12641451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rational design of potent and selective NH-linked aryl/heteroaryl cathepsin K inhibitors.
    Robichaud J; Bayly C; Oballa R; Prasit P; Mellon C; Falgueyret JP; Percival MD; Wesolowski G; Rodan SB
    Bioorg Med Chem Lett; 2004 Aug; 14(16):4291-5. PubMed ID: 15261289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery and SAR of novel pyrazole-based thioethers as cathepsin S inhibitors: part 1.
    Lee-Dutra A; Wiener DK; Arienti KL; Liu J; Mani N; Ameriks MK; Axe FU; Gebauer D; Desai PJ; Nguyen S; Randal M; Thurmond RL; Sun S; Karlsson L; Edwards JP; Jones TK; Grice CA
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2370-4. PubMed ID: 20153648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A structural screening approach to ketoamide-based inhibitors of cathepsin K.
    Barrett DG; Catalano JG; Deaton DN; Long ST; McFadyen RB; Miller AB; Miller LR; Wells-Knecht KJ; Wright LL
    Bioorg Med Chem Lett; 2005 May; 15(9):2209-13. PubMed ID: 15837295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diazinones as P2 replacements for pyrazole-based cathepsin S inhibitors.
    Ameriks MK; Bembenek SD; Burdett MT; Choong IC; Edwards JP; Gebauer D; Gu Y; Karlsson L; Purkey HE; Staker BL; Sun S; Thurmond RL; Zhu J
    Bioorg Med Chem Lett; 2010 Jul; 20(14):4060-4. PubMed ID: 20541404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pyrazole-based cathepsin S inhibitors with arylalkynes as P1 binding elements.
    Ameriks MK; Axe FU; Bembenek SD; Edwards JP; Gu Y; Karlsson L; Randal M; Sun S; Thurmond RL; Zhu J
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6131-4. PubMed ID: 19773165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ketoheterocycle-based inhibitors of cathepsin K: a novel entry into the synthesis of peptidic ketoheterocycles.
    Tavares FX; Deaton DN; Miller AB; Miller LR; Wright LL
    Bioorg Med Chem Lett; 2005 Sep; 15(17):3891-5. PubMed ID: 15993587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natural biflavones as novel inhibitors of cathepsin B and K.
    Zeng GZ; Pan XL; Tan NH; Xiong J; Zhang YM
    Eur J Med Chem; 2006 Nov; 41(11):1247-52. PubMed ID: 16828525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of selective, nonpeptidic nitrile inhibitors of cathepsin s using the substrate activity screening method.
    Patterson AW; Wood WJ; Hornsby M; Lesley S; Spraggon G; Ellman JA
    J Med Chem; 2006 Oct; 49(21):6298-307. PubMed ID: 17034136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery and SAR of novel pyrazole-based thioethers as cathepsin S inhibitors. Part 2: Modification of P3, P4, and P5 regions.
    Wiener JJ; Wickboldt AT; Wiener DK; Lee-Dutra A; Edwards JP; Karlsson L; Nguyen S; Sun S; Jones TK; Grice CA
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2375-8. PubMed ID: 20171097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors.
    Yamashita DS; Marquis RW; Xie R; Nidamarthy SD; Oh HJ; Jeong JU; Erhard KF; Ward KW; Roethke TJ; Smith BR; Cheng HY; Geng X; Lin F; Offen PH; Wang B; Nevins N; Head MS; Haltiwanger RC; Narducci Sarjeant AA; Liable-Sands LM; Zhao B; Smith WW; Janson CA; Gao E; Tomaszek T; McQueney M; James IE; Gress CJ; Zembryki DL; Lark MW; Veber DF
    J Med Chem; 2006 Mar; 49(5):1597-612. PubMed ID: 16509577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Orally bioavailable small molecule ketoamide-based inhibitors of cathepsin K.
    Barrett DG; Catalano JG; Deaton DN; Long ST; Miller LR; Tavares FX; Wells-Knecht KJ; Wright LL; Zhou HQ
    Bioorg Med Chem Lett; 2004 May; 14(10):2543-6. PubMed ID: 15109647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel potential mechanism-based inhibitors of human leukocyte elastase and cathepsin G: derivatives of isothiazolidin-3-one.
    Groutas WC; Chong LS; Venkataraman R
    Biochem Biophys Res Commun; 1993 Dec; 197(2):730-9. PubMed ID: 8267609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploration of cathepsin S inhibitors characterized by a triazole P1-P2 amide replacement.
    Moss N; Xiong Z; Burke M; Cogan D; Gao DA; Haverty K; Heim-Riether A; Hickey ER; Nagaraja R; Netherton M; O'Shea K; Ramsden P; Schwartz R; Shih DT; Ward Y; Young E; Zhang Q
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7189-93. PubMed ID: 23084902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New potent cathepsin G phosphonate inhibitors.
    Sieńczyk M; Lesner A; Wysocka M; Legowska A; Pietrusewicz E; Rolka K; Oleksyszyn J
    Bioorg Med Chem; 2008 Oct; 16(19):8863-7. PubMed ID: 18805698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pyrazole-based cathepsin S inhibitors with improved cellular potency.
    Wei J; Pio BA; Cai H; Meduna SP; Sun S; Gu Y; Jiang W; Thurmond RL; Karlsson L; Edwards JP
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5525-8. PubMed ID: 17822900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 4-(3-Trifluoromethylphenyl)-pyrimidine-2-carbonitrile as cathepsin S inhibitors: N3, not N1 is critically important.
    Cai J; Fradera X; van Zeeland M; Dempster M; Cameron KS; Bennett DJ; Robinson J; Popplestone L; Baugh M; Westwood P; Bruin J; Hamilton W; Kinghorn E; Long C; Uitdehaag JC
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4507-10. PubMed ID: 20580231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.